BioSpace News Archive

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of $0.60 per share.

Waters Corporation announced it is providing both technology and expertise to help advance plant-based protein science in collaboration with researchers of the Plant Protein Innovation Center at the University of Minnesota.

Spectrum Solutions, LLC announced the publishing of findings from their research collaboration with the University of California at Los Angeles and Dr. David Wong, UCLA School of Dentistry.

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the European approval for a patent covering the clinical use of a biomarker analysis to detect cancer patients ability to respond to folate-based therapy cancer treatments and an intention-to-grant patent application for a patent covering the AGENT study dose regimen in Europe.

SOTIO Biotech announced today that the first patient was dosed in its Phase 2, AURELIO-04 combination trial.

Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner, Ph.D., as Chief Scientific Officer.

KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that members of the KemPharm team will attend the upcoming Niemann Pick Disease Foundation’s Family Support and Medical Conference.

Gracell Biotechnologies Inc. today announced that the management team will participate in BTIG 2022 Hybrid Biotechnology Conference in August 2022.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2022 financial results after market close on Tuesday, August 2 , 2022.

HeartBeam, Inc . (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday August 11, 2022 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones.